Agricultural productivity may be raised in a sustainable way by many different technologies such as biological fertilizers, soil and water conservation, biodiversity conservation, improved pest control, and changes in...Agricultural productivity may be raised in a sustainable way by many different technologies such as biological fertilizers, soil and water conservation, biodiversity conservation, improved pest control, and changes in land ownership and distribution. Of these measures, biotechnology applications probably hold the most promise in augmenting conventional agricultural productivity, because biotechnology applications give not only the need to increase production, but also protect the environment and conserving natural resources for future generations. Biotechnology applications will have the possibilities to increase productivity and food availability through better agronomic performance of new varieties, including resistance to pests; rapid multiplication of disease-free plants; ability to obtain natural plant products using tissue culture; diagnosis of diseases of plants and livestock; manipulation of reproduction methods increasing the efficiency of breeding; and the provision of incentives for greater participation by the private sector through investments. Insect resistance through the transfer of a gene for resistance fromBacillus thuringiensis (Bt) is one of the most advanced biotechnology applications already being commercialized in many parts of the world. This paper reviews the development and the status ofBt technology and application ofBt transgenic plants in current agriculture, and discusses specific issues related to the transfer of the technology to the future of genetic engineered trees with emphasis on conifers. Key words Agricultural productivity - Bacillus thuringiensis - Genetic engineering - Insect resistance - Trees CLC number Q812 - S763.306 Document code A Biography: Tang Wei (1964-), male, Ph. Doctor, Research associate, Department of Biology, Howell Science Complex, East Carelina University, Greenville, NC 27858-4353, USA.Responsible editor: Chal Ruihai展开更多
The Bacillus strain BH072 isolated from a honey sample showed strong antifungal activity against phytopathogen. Gene cloning test demonstrated that the strain had a tasA gene encoding an antifungal TasA protein. Altho...The Bacillus strain BH072 isolated from a honey sample showed strong antifungal activity against phytopathogen. Gene cloning test demonstrated that the strain had a tasA gene encoding an antifungal TasA protein. Although the wild strain simultaneously produced various antifungal substances, only the physicochemical property and antifungal activity of TasA protein were unclear due to the difficulty in extraction. In this study, tasA gene encoding the protein from Bacillus sp. BH072 was amplified by using the polymerase chain reaction (PCR) method and cloned into pET 28a (+) vector, and then expressed in host cells Escherichia coli BL21 (DE3). The expressed proteins were collected by centrifugation and ultrasonic treatment, and then purified by using nickel-nitrilotriacetic acid (Ni-NTA) metal affinity column and dialysis methods. The result of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) test showed that an expected protein band appeared with a size of 31 kDa. The expressed products possessed antifungal activity against the phytopathogenic indicator strain Botrytis cinerea. A genetically engineered strain tasA orE, coli was established in this study which can efficiently express Tas A protein.展开更多
T cell mediated adoptive immune response has been characterized as the key to anti-tumor immunity. Scientists around the world including in China, have been trying to harness the power of T cells against tumors for de...T cell mediated adoptive immune response has been characterized as the key to anti-tumor immunity. Scientists around the world including in China, have been trying to harness the power of T cells against tumors for decades. Recently, the biosynthetic chimeric antigen receptor engineered T cell(CAR-T) strategy was developed and exhibited encouraging clinical efficacy, especially in hematological malignancies. Chimeric antigen receptor research reports began in 2009 in China according to our Pub Med search results. Clinical trials have been ongoing in China since 2013 according to the trial registrations on clinicaltrials.gov.. After years of assiduous efforts, research and clinical scientists in China have made their own achievements in the CAR-T therapy field. In this review, we aim to highlight CAR-T research and clinical trials in China, to provide an informative reference for colleagues in the field.展开更多
A new method to screen antibiotic combinations is demonstrated,which takes advantage of the logic-signal output of genetically engineered drug-resistant E.coli strains expressing different fluorescent proteins.Thirty-...A new method to screen antibiotic combinations is demonstrated,which takes advantage of the logic-signal output of genetically engineered drug-resistant E.coli strains expressing different fluorescent proteins.Thirty-six antibiotic combinations for nine antibiotics were investigated.The operation of different logic gates can reveal the susceptibility,resistance,or synergistic effect of the antibiotic combinations in a rapid(7–8 h versus 24–28 h for typical growth-based assays),simple,quantitative and high-throughput manner.This logic-signal-based output patterns provide the basis for novel and reliable screening of antibiotic combinations and help us to both gain insight into the mechanisms of multi-drug action.展开更多
The development of genetic engineering has enabled the modification of stem cells and somatic cells.T cells exert immune responses against cancer cells.Efforts to redirect T cell specificity of a chimeric antigen rece...The development of genetic engineering has enabled the modification of stem cells and somatic cells.T cells exert immune responses against cancer cells.Efforts to redirect T cell specificity of a chimeric antigen receptor(CAR)to a desired antigen began in the 1990s(Gross et al.,1989;Kuwana et al.,1987).In 2006,the first clinical trial using carbonic anhydrase IX CAR-T cells to fight renal cancer was conducted(Lamers et al.,2006).Until 2011,Porter et al.exploited CD19 CAR-T to treat refractory/relapsed chronic lymphoid leukemia(Porter et al.,2011).Subsequently。展开更多
文摘Agricultural productivity may be raised in a sustainable way by many different technologies such as biological fertilizers, soil and water conservation, biodiversity conservation, improved pest control, and changes in land ownership and distribution. Of these measures, biotechnology applications probably hold the most promise in augmenting conventional agricultural productivity, because biotechnology applications give not only the need to increase production, but also protect the environment and conserving natural resources for future generations. Biotechnology applications will have the possibilities to increase productivity and food availability through better agronomic performance of new varieties, including resistance to pests; rapid multiplication of disease-free plants; ability to obtain natural plant products using tissue culture; diagnosis of diseases of plants and livestock; manipulation of reproduction methods increasing the efficiency of breeding; and the provision of incentives for greater participation by the private sector through investments. Insect resistance through the transfer of a gene for resistance fromBacillus thuringiensis (Bt) is one of the most advanced biotechnology applications already being commercialized in many parts of the world. This paper reviews the development and the status ofBt technology and application ofBt transgenic plants in current agriculture, and discusses specific issues related to the transfer of the technology to the future of genetic engineered trees with emphasis on conifers. Key words Agricultural productivity - Bacillus thuringiensis - Genetic engineering - Insect resistance - Trees CLC number Q812 - S763.306 Document code A Biography: Tang Wei (1964-), male, Ph. Doctor, Research associate, Department of Biology, Howell Science Complex, East Carelina University, Greenville, NC 27858-4353, USA.Responsible editor: Chal Ruihai
文摘The Bacillus strain BH072 isolated from a honey sample showed strong antifungal activity against phytopathogen. Gene cloning test demonstrated that the strain had a tasA gene encoding an antifungal TasA protein. Although the wild strain simultaneously produced various antifungal substances, only the physicochemical property and antifungal activity of TasA protein were unclear due to the difficulty in extraction. In this study, tasA gene encoding the protein from Bacillus sp. BH072 was amplified by using the polymerase chain reaction (PCR) method and cloned into pET 28a (+) vector, and then expressed in host cells Escherichia coli BL21 (DE3). The expressed proteins were collected by centrifugation and ultrasonic treatment, and then purified by using nickel-nitrilotriacetic acid (Ni-NTA) metal affinity column and dialysis methods. The result of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) test showed that an expected protein band appeared with a size of 31 kDa. The expressed products possessed antifungal activity against the phytopathogenic indicator strain Botrytis cinerea. A genetically engineered strain tasA orE, coli was established in this study which can efficiently express Tas A protein.
基金supported by Science and Technology Planning Project of Beijing City (Z151100003915076 to Weidong Han)National Natural Science Foundation of China (31270820, 81230061 to Weidong Han, 81502679 to Can Luo)
文摘T cell mediated adoptive immune response has been characterized as the key to anti-tumor immunity. Scientists around the world including in China, have been trying to harness the power of T cells against tumors for decades. Recently, the biosynthetic chimeric antigen receptor engineered T cell(CAR-T) strategy was developed and exhibited encouraging clinical efficacy, especially in hematological malignancies. Chimeric antigen receptor research reports began in 2009 in China according to our Pub Med search results. Clinical trials have been ongoing in China since 2013 according to the trial registrations on clinicaltrials.gov.. After years of assiduous efforts, research and clinical scientists in China have made their own achievements in the CAR-T therapy field. In this review, we aim to highlight CAR-T research and clinical trials in China, to provide an informative reference for colleagues in the field.
基金financially supported by the National Natural Science Foundation of China(21203213)the Major Research Plan of China(2013CB932800,2012CB932600)
文摘A new method to screen antibiotic combinations is demonstrated,which takes advantage of the logic-signal output of genetically engineered drug-resistant E.coli strains expressing different fluorescent proteins.Thirty-six antibiotic combinations for nine antibiotics were investigated.The operation of different logic gates can reveal the susceptibility,resistance,or synergistic effect of the antibiotic combinations in a rapid(7–8 h versus 24–28 h for typical growth-based assays),simple,quantitative and high-throughput manner.This logic-signal-based output patterns provide the basis for novel and reliable screening of antibiotic combinations and help us to both gain insight into the mechanisms of multi-drug action.
文摘The development of genetic engineering has enabled the modification of stem cells and somatic cells.T cells exert immune responses against cancer cells.Efforts to redirect T cell specificity of a chimeric antigen receptor(CAR)to a desired antigen began in the 1990s(Gross et al.,1989;Kuwana et al.,1987).In 2006,the first clinical trial using carbonic anhydrase IX CAR-T cells to fight renal cancer was conducted(Lamers et al.,2006).Until 2011,Porter et al.exploited CD19 CAR-T to treat refractory/relapsed chronic lymphoid leukemia(Porter et al.,2011).Subsequently。